Mitesh

Class 4 Medicines Defect Information: Sodium Chloride 0.9% Intravenous Infusion BP Freeflex and Freeflex PLUS (Fresenius Kabi Limited) Drug alert number: EL (24)A/17 Date issued: 22 May 2024 The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 medicines defect information notice for: Sodium Chloride 0.9% Intravenous Infusion BP Freeflex and Freeflex PLUS [...]

The post MHRA Class 4 Medicines Notification: Sodium Chloride 0.9% Intravenous Infusion BP Freeflex and Freeflex PLUS (Fresenius Kabi Limited) appeared first on Community Pharmacy England.

The Department of Health and Social Care (DHSC) has provided an update on the Serious Shortage Protocols (SSPs) for Clarithromycin 125mg/5ml and 250mg/5ml oral suspensions (SSP053 and SSP054). SSP053 and SSP054 were due to expire on 21 June but the end date has been further extended to Friday 19 July 2024. In response to a [...]

The post Two Clarithromycin SSPs extended appeared first on Community Pharmacy England.

Class 4 Medicines Defect Information: Trazodone hydrochloride 50mg/5ml oral solution (Cygnus Pharma Ltd) Drug alert number: EL (24)A/16 Date issued: 20 May 2024 The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 medicines defect information notice for: Trazodone hydrochloride 50mg/5ml oral solution (Cygnus Pharma Ltd) Company name: Cygnus Pharma Ltd Product name: [...]

The post MHRA Class 4 Medicines Notification: Trazodone hydrochloride 50mg/5ml oral solution (Cygnus Pharma Ltd) appeared first on Community Pharmacy England.

In light of surveillance data indicating that circulation of influenza in the community has returned to baseline levels, the Department of Health and Social Care has published an alert to inform prescribers working in primary care and pharmacy teams that antiviral medicines should no longer be prescribed.  Community pharmacists should no longer supply antiviral medicines [...]

The post End of antiviral medicine prescribing for 2023/24 influenza season appeared first on Community Pharmacy England.

A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (Vol 17 Issue 9 April 2024) has been published and includes articles on: Finasteride: reminder of the risk of psychiatric side effects and of sexual side effects (which may persist after discontinuation of treatment) Montelukast: reminder of the risk of neuropsychiatric reactions Letters [...]

The post MHRA Drug Safety Update: April 2024 appeared first on Community Pharmacy England.